FXR agonists targeting the gut-liver axis are promising for NAFLD/NASH for they not only relieve hepatic steatosis but also resolve fibrosis at histology level by antagonizing NFκB [285, 286]. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.